Temozolomide (NSC 362856), DNA Alkylator
Por um escritor misterioso
Descrição
Temozolomide (NSC 362856) is an oral active DNA alkylating agent that crosses the blood-brain barrier. Temozolomide is also a proautophagic and proapoptotic agent. Temozolomide is effective against tumor cells that are characterized by low levels of O6-alkylguanine DNA alkyltransferase (OGAT) and a functional mismatch repair system. Temozolomide has antitumor and antiangiogenic effects. - Mechanism of Action & Protocol.
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture
Current and future developments in the use of temozolomide for the treatment of brain tumours - The Lancet Oncology
Temozolomide resistance in glioblastoma multiforme - ScienceDirect
Novel strategies of Raman imaging for monitoring the therapeutic benefit of temozolomide in glioblastoma - ScienceDirect
Autophagy enhancement contributes to the synergistic effect of vitamin D in temozolomide‑based glioblastoma chemotherapy
Biomedicines, Free Full-Text
Novel Imidazotetrazine Evades Known Resistance Mechanisms and Is Effective against Temozolomide-Resistant Brain Cancer in Cell Culture
Temozolomide, CAS 85622-93-1
Frontiers An overview of glioblastoma multiforme and temozolomide resistance: can LC-MS-based proteomics reveal the fundamental mechanism of temozolomide resistance?
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules
Temozolomide - an overview
Tunable Stability of Imidazotetrazines Leads to a Potent Compound for Glioblastoma
de
por adulto (o preço varia de acordo com o tamanho do grupo)
